Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study
Open Access
- 9 November 2026
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- p. 1-34
Abstract
1. The transition from intravenous (IV) to subcutaneous (SC) delivery of biotherapeutics, such as monoclonal antibodies (mAbs), is prominent for a variety of reasons. Perhaps the most important is ...Keywords
Funding Information
- Matchstick LLC
- AstraZeneca
This publication has 135 references indexed in Scilit:
- Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world studyBreast Cancer, 2025
- Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery systemJournal of Cancer Research and Clinical Oncology, 2025
- Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentClinical Pharmacology & Therapeutics, 2024
- Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion RegimensJournal of Clinical Immunology, 2023
- Analysis of a Remote Monitoring Program for Symptoms Among Adults With Cancer Receiving Antineoplastic TherapyJAMA Network Open, 2022
- Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy VolunteersClinical Pharmacology & Therapeutics, 2021
- Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancerBreast Cancer Research and Treatment, 2020
- Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency PatientsJournal of Clinical Immunology, 2018
- A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancerCancer Medicine, 2016
- Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesCancer Chemotherapy and Pharmacology, 2013